Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?
Aims: To assess whether heterogeneity of epidermal growth factor receptor (EGFR) immunoreactivity in renal cell carcinoma (RCC) is related to non-standardised criteria for staining evaluation. Methods: EGFR expression was investigated in 132 primary and 55 metastatic conventional RCCs using a tissue...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pathology 2004-07, Vol.57 (7), p.773-775 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 775 |
|---|---|
| container_issue | 7 |
| container_start_page | 773 |
| container_title | Journal of clinical pathology |
| container_volume | 57 |
| creator | Langner, C Ratschek, M Rehak, P Schips, L Zigeuner, R |
| description | Aims: To assess whether heterogeneity of epidermal growth factor receptor (EGFR) immunoreactivity in renal cell carcinoma (RCC) is related to non-standardised criteria for staining evaluation. Methods: EGFR expression was investigated in 132 primary and 55 metastatic conventional RCCs using a tissue microarray technique. Results: Overall, membranous and/or cytoplasmic EGFR immunostaining was present in 123 of 132 (93%) primary and 49 of 53 (92%) metastatic RCCs, with extensive immunoreactivity (> 50% of tumour cells) in 110 of 132 (83%) primary tumours and 39 of 53 (73%) metastases. Cytoplasmic staining was associated with high tumour stage and high tumour grade. In addition, strong membranous staining (score 3+) prevailed in high grade RCCs. Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not. Conclusions: Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially against a background of rapidly evolving EGFR targeted cancer treatment strategies. |
| doi_str_mv | 10.1136/jcp.2003.015743 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1770368</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66661455</sourcerecordid><originalsourceid>FETCH-LOGICAL-b520t-f341d0fc37d4114acbd1967271c4648e309bd45938b75df02eaab7c120a35c613</originalsourceid><addsrcrecordid>eNqFkcFv0zAUxiMEYt3gzA1ZQnBASucXO3FzGZq6dSCqISHYgYv14jidS2IX26nYX8C_jatWY3DBB1t67-fPz9-XZS-ATgFYdbpWm2lBKZtSKAVnj7IJcFHkHHj1OJtQWkBeC14dZcchrCkFJoA9zY6gLArKRDXJfp17TW511N6ttHVjIF6HsY-BuI5cXi0-EzMMo3Veo4pma-IdMTYxFnuidJ829MpYN2Aq9hh1S6Ij1tk8RLQt-taEVFPepCcMks55kjrGGrsieov9iNE4--5Z9qTDPujnh_Mk-7q4_DJ_ny8_XX2Yny_zpixozDvGoaWdYqLlABxV00JdiUKA4hWfaUbrpuVlzWaNKNuOFhqxEQoKiqxUFbCT7GyvuxmbQbdK2-ixlxtvBvR30qGRf3esuZUrt5UgBGXVLAm8OQh492PUIcrBhJ0TaHWyT1ZpAS_LBL76B1y70SffQtKaAS14yapEne4p5V0IXnf3owCVu4hliljuIpb7iNONlw9_8Ic_ZJqA1wcAg8K-82iVCQ-4WpQAOyvyPWdC1D_v--i_y0owUcrrm7msL-pvH2-ul3KR-Ld7vhnW_53yNzlrzgw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781024536</pqid></control><display><type>article</type><title>Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Langner, C ; Ratschek, M ; Rehak, P ; Schips, L ; Zigeuner, R</creator><creatorcontrib>Langner, C ; Ratschek, M ; Rehak, P ; Schips, L ; Zigeuner, R</creatorcontrib><description>Aims: To assess whether heterogeneity of epidermal growth factor receptor (EGFR) immunoreactivity in renal cell carcinoma (RCC) is related to non-standardised criteria for staining evaluation. Methods: EGFR expression was investigated in 132 primary and 55 metastatic conventional RCCs using a tissue microarray technique. Results: Overall, membranous and/or cytoplasmic EGFR immunostaining was present in 123 of 132 (93%) primary and 49 of 53 (92%) metastatic RCCs, with extensive immunoreactivity (> 50% of tumour cells) in 110 of 132 (83%) primary tumours and 39 of 53 (73%) metastases. Cytoplasmic staining was associated with high tumour stage and high tumour grade. In addition, strong membranous staining (score 3+) prevailed in high grade RCCs. Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not. Conclusions: Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially against a background of rapidly evolving EGFR targeted cancer treatment strategies.</description><identifier>ISSN: 0021-9746</identifier><identifier>EISSN: 1472-4146</identifier><identifier>DOI: 10.1136/jcp.2003.015743</identifier><identifier>PMID: 15220376</identifier><identifier>CODEN: JCPAAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and Association of Clinical Pathologists</publisher><subject>Angiogenesis ; Apoptosis ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Cancer ; Cancer therapies ; Carcinoma, Renal Cell - chemistry ; Carcinoma, Renal Cell - secondary ; Cell cycle ; Cell Membrane - chemistry ; Cytoplasm - chemistry ; EGFR ; Epidermal growth factor ; epidermal growth factor receptor ; Humans ; immunohistochemical evaluation ; Investigative techniques, diagnostic techniques (general aspects) ; Kidney Neoplasms - chemistry ; Kidney Neoplasms - pathology ; Kidneys ; Kinases ; Medical prognosis ; Medical sciences ; Metastasis ; Methods ; Molecular weight ; Multivariate analysis ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Prognosis ; Protein Array Analysis - methods ; Protein Array Analysis - standards ; RCC ; Reagent Kits, Diagnostic - standards ; Receptor, Epidermal Growth Factor - analysis ; renal cell carcinoma ; Reproducibility of Results ; Short Reports ; Signal transduction ; Studies ; treatment ; Tumors ; Tumors of the urinary system</subject><ispartof>Journal of clinical pathology, 2004-07, Vol.57 (7), p.773-775</ispartof><rights>Copyright 2004 Journal of Clinical Pathology</rights><rights>2004 INIST-CNRS</rights><rights>Copyright: 2004 Copyright 2004 Journal of Clinical Pathology</rights><rights>Copyright © Copyright 2004 Journal of Clinical Pathology 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b520t-f341d0fc37d4114acbd1967271c4648e309bd45938b75df02eaab7c120a35c613</citedby><cites>FETCH-LOGICAL-b520t-f341d0fc37d4114acbd1967271c4648e309bd45938b75df02eaab7c120a35c613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1770368/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1770368/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15975111$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15220376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Langner, C</creatorcontrib><creatorcontrib>Ratschek, M</creatorcontrib><creatorcontrib>Rehak, P</creatorcontrib><creatorcontrib>Schips, L</creatorcontrib><creatorcontrib>Zigeuner, R</creatorcontrib><title>Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?</title><title>Journal of clinical pathology</title><addtitle>J Clin Pathol</addtitle><description>Aims: To assess whether heterogeneity of epidermal growth factor receptor (EGFR) immunoreactivity in renal cell carcinoma (RCC) is related to non-standardised criteria for staining evaluation. Methods: EGFR expression was investigated in 132 primary and 55 metastatic conventional RCCs using a tissue microarray technique. Results: Overall, membranous and/or cytoplasmic EGFR immunostaining was present in 123 of 132 (93%) primary and 49 of 53 (92%) metastatic RCCs, with extensive immunoreactivity (> 50% of tumour cells) in 110 of 132 (83%) primary tumours and 39 of 53 (73%) metastases. Cytoplasmic staining was associated with high tumour stage and high tumour grade. In addition, strong membranous staining (score 3+) prevailed in high grade RCCs. Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not. Conclusions: Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially against a background of rapidly evolving EGFR targeted cancer treatment strategies.</description><subject>Angiogenesis</subject><subject>Apoptosis</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Renal Cell - chemistry</subject><subject>Carcinoma, Renal Cell - secondary</subject><subject>Cell cycle</subject><subject>Cell Membrane - chemistry</subject><subject>Cytoplasm - chemistry</subject><subject>EGFR</subject><subject>Epidermal growth factor</subject><subject>epidermal growth factor receptor</subject><subject>Humans</subject><subject>immunohistochemical evaluation</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Kidney Neoplasms - chemistry</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidneys</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Molecular weight</subject><subject>Multivariate analysis</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Prognosis</subject><subject>Protein Array Analysis - methods</subject><subject>Protein Array Analysis - standards</subject><subject>RCC</subject><subject>Reagent Kits, Diagnostic - standards</subject><subject>Receptor, Epidermal Growth Factor - analysis</subject><subject>renal cell carcinoma</subject><subject>Reproducibility of Results</subject><subject>Short Reports</subject><subject>Signal transduction</subject><subject>Studies</subject><subject>treatment</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><issn>0021-9746</issn><issn>1472-4146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkcFv0zAUxiMEYt3gzA1ZQnBASucXO3FzGZq6dSCqISHYgYv14jidS2IX26nYX8C_jatWY3DBB1t67-fPz9-XZS-ATgFYdbpWm2lBKZtSKAVnj7IJcFHkHHj1OJtQWkBeC14dZcchrCkFJoA9zY6gLArKRDXJfp17TW511N6ttHVjIF6HsY-BuI5cXi0-EzMMo3Veo4pma-IdMTYxFnuidJ829MpYN2Aq9hh1S6Ij1tk8RLQt-taEVFPepCcMks55kjrGGrsieov9iNE4--5Z9qTDPujnh_Mk-7q4_DJ_ny8_XX2Yny_zpixozDvGoaWdYqLlABxV00JdiUKA4hWfaUbrpuVlzWaNKNuOFhqxEQoKiqxUFbCT7GyvuxmbQbdK2-ixlxtvBvR30qGRf3esuZUrt5UgBGXVLAm8OQh492PUIcrBhJ0TaHWyT1ZpAS_LBL76B1y70SffQtKaAS14yapEne4p5V0IXnf3owCVu4hliljuIpb7iNONlw9_8Ic_ZJqA1wcAg8K-82iVCQ-4WpQAOyvyPWdC1D_v--i_y0owUcrrm7msL-pvH2-ul3KR-Ld7vhnW_53yNzlrzgw</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Langner, C</creator><creator>Ratschek, M</creator><creator>Rehak, P</creator><creator>Schips, L</creator><creator>Zigeuner, R</creator><general>BMJ Publishing Group Ltd and Association of Clinical Pathologists</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>Copyright 2004 Journal of Clinical Pathology</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20040701</creationdate><title>Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?</title><author>Langner, C ; Ratschek, M ; Rehak, P ; Schips, L ; Zigeuner, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b520t-f341d0fc37d4114acbd1967271c4648e309bd45938b75df02eaab7c120a35c613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Angiogenesis</topic><topic>Apoptosis</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Renal Cell - chemistry</topic><topic>Carcinoma, Renal Cell - secondary</topic><topic>Cell cycle</topic><topic>Cell Membrane - chemistry</topic><topic>Cytoplasm - chemistry</topic><topic>EGFR</topic><topic>Epidermal growth factor</topic><topic>epidermal growth factor receptor</topic><topic>Humans</topic><topic>immunohistochemical evaluation</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Kidney Neoplasms - chemistry</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidneys</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Molecular weight</topic><topic>Multivariate analysis</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Prognosis</topic><topic>Protein Array Analysis - methods</topic><topic>Protein Array Analysis - standards</topic><topic>RCC</topic><topic>Reagent Kits, Diagnostic - standards</topic><topic>Receptor, Epidermal Growth Factor - analysis</topic><topic>renal cell carcinoma</topic><topic>Reproducibility of Results</topic><topic>Short Reports</topic><topic>Signal transduction</topic><topic>Studies</topic><topic>treatment</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Langner, C</creatorcontrib><creatorcontrib>Ratschek, M</creatorcontrib><creatorcontrib>Rehak, P</creatorcontrib><creatorcontrib>Schips, L</creatorcontrib><creatorcontrib>Zigeuner, R</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Langner, C</au><au>Ratschek, M</au><au>Rehak, P</au><au>Schips, L</au><au>Zigeuner, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?</atitle><jtitle>Journal of clinical pathology</jtitle><addtitle>J Clin Pathol</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>57</volume><issue>7</issue><spage>773</spage><epage>775</epage><pages>773-775</pages><issn>0021-9746</issn><eissn>1472-4146</eissn><coden>JCPAAK</coden><abstract>Aims: To assess whether heterogeneity of epidermal growth factor receptor (EGFR) immunoreactivity in renal cell carcinoma (RCC) is related to non-standardised criteria for staining evaluation. Methods: EGFR expression was investigated in 132 primary and 55 metastatic conventional RCCs using a tissue microarray technique. Results: Overall, membranous and/or cytoplasmic EGFR immunostaining was present in 123 of 132 (93%) primary and 49 of 53 (92%) metastatic RCCs, with extensive immunoreactivity (> 50% of tumour cells) in 110 of 132 (83%) primary tumours and 39 of 53 (73%) metastases. Cytoplasmic staining was associated with high tumour stage and high tumour grade. In addition, strong membranous staining (score 3+) prevailed in high grade RCCs. Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not. Conclusions: Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially against a background of rapidly evolving EGFR targeted cancer treatment strategies.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and Association of Clinical Pathologists</pub><pmid>15220376</pmid><doi>10.1136/jcp.2003.015743</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9746 |
| ispartof | Journal of clinical pathology, 2004-07, Vol.57 (7), p.773-775 |
| issn | 0021-9746 1472-4146 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1770368 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Angiogenesis Apoptosis Biological and medical sciences Biomarkers, Tumor - analysis Cancer Cancer therapies Carcinoma, Renal Cell - chemistry Carcinoma, Renal Cell - secondary Cell cycle Cell Membrane - chemistry Cytoplasm - chemistry EGFR Epidermal growth factor epidermal growth factor receptor Humans immunohistochemical evaluation Investigative techniques, diagnostic techniques (general aspects) Kidney Neoplasms - chemistry Kidney Neoplasms - pathology Kidneys Kinases Medical prognosis Medical sciences Metastasis Methods Molecular weight Multivariate analysis Neoplasm Staging Nephrology. Urinary tract diseases Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Prognosis Protein Array Analysis - methods Protein Array Analysis - standards RCC Reagent Kits, Diagnostic - standards Receptor, Epidermal Growth Factor - analysis renal cell carcinoma Reproducibility of Results Short Reports Signal transduction Studies treatment Tumors Tumors of the urinary system |
| title | Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T03%3A56%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20heterogenous%20results%20of%20EGFR%20immunoreactivity%20in%20renal%20cell%20carcinoma%20related%20to%20non-standardised%20criteria%20for%20staining%20evaluation?&rft.jtitle=Journal%20of%20clinical%20pathology&rft.au=Langner,%20C&rft.date=2004-07-01&rft.volume=57&rft.issue=7&rft.spage=773&rft.epage=775&rft.pages=773-775&rft.issn=0021-9746&rft.eissn=1472-4146&rft.coden=JCPAAK&rft_id=info:doi/10.1136/jcp.2003.015743&rft_dat=%3Cproquest_pubme%3E66661455%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781024536&rft_id=info:pmid/15220376&rfr_iscdi=true |